Abstract
Proteins are already used for more than 100 years to treat or prevent diseases in humans. It started in the early 1890s with “serum therapy” for the treatment of diphtheria and tetanus by Emile von Behring and others. The antiserum was obtained from immunized rabbits and horses. Behring received the Nobel Prize for Medicine in 1901 for this pioneering work on passive immunization. A next big step in the development of therapeutic proteins was the use of purified insulin isolated from pig or cow pancreas for the treatment of diabetes type I in the early 1920s by Banting and Best (in 1923 Banting received the Nobel Prize for this work). Soon after the discovery of insulin, the pharmaceutical company Eli Lilly started large-scale production of the pancreatic extracts for the treatment of diabetes. Within 3 years after the start of the experiments by Banting, already enough animal-derived insulin was produced to supply the entire North American continent. Compare this to the present average time-to-market of a new drug (from discovery to approval) of 13.5 years (Paul et al. 2010).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Recommended Reading and References
Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P (2007) Molecular biology of the cell. Garland Science, New York
Berg JM, Tymoczko JL, Stryer L (2011) Biochemistry, 7th edn. WH. Freeman & CO., New York
Brekke OH, Sandlie I (2003) Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov 2(1):52–62
Wikepedia. Available at: http://en.wikipedia.org
Kashmiri SV, De Pascalis R, Gonzales NR, Schlom J (2005) SDR grafting-a new approach to antibody humanization. Methods 36(1):25–34
Kircher M, Kelso J (2010) High-throughput DNA sequencing–concepts and limitations. Bioessays 32(6):524–536
Leader B, Baca QJ, Golan DE (2008) Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 7(1):21–39
Lodish H, Berk A, Kaiser CA, Krieger M, Scott MP (2007) Molecular cell biology, 6th edn. WH. Freeman & CO., New York
Nothaft H, Szymanski CM (2010) Protein glycosylation in bacteria: sweeter than ever. Nat Rev Microbiol 8(11):765–778
Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL (2010) How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov 9(3):203–214
Strohl WR, Knight DM (2009) Discovery and development of biopharmaceuticals: current issues. Curr Opin Biotechnol 20(6):668–672
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Oosting, R.S. (2013). Molecular Biotechnology: From DNA Sequence to Therapeutic Protein. In: Crommelin, D., Sindelar, R., Meibohm, B. (eds) Pharmaceutical Biotechnology. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6486-0_1
Download citation
DOI: https://doi.org/10.1007/978-1-4614-6486-0_1
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-6485-3
Online ISBN: 978-1-4614-6486-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)